Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Frontage HoldingsHKSE:01521 -0.40%89 Days Payable is 20.43 as of Dec. 2025, which is 14% below its 10-year median of 23.81. GuruFocus rates HKSE:01521 with a GF Score™ of 89/100 and a GF Value™ of HK$1.55 (Modestly Undervalued). The stock has 8 warning signs investors should review. Among 704 Biotechnology companies, Frontage Holdings ranks worse than 89.35% on this metric.
The historical rank and industry rank for Frontage Holdings's Days Payable or its related term are showing as below:
HKSE:01521'
s Days Payable Range Over the Past 10 Years
Min: 15.94 Med: 23.81 Max: 29.18
Current: 19.51
During the past 10 years, Frontage Holdings's highest Days Payable was 29.18. The lowest was 15.94. And the median was 23.81.
HKSE:01521's Days Payable is ranked worse than 89.35% of 704
companies
in the Biotechnology industry
Industry Median: 112.715
vs HKSE:01521: 19.51
Frontage Holdings's Days Payable
increased
from Dec. 2024 (19.96) to Dec. 2025 (20.43).
It may suggest that Frontage Holdingsdelayed paying its suppliers.
The historical data trend for Frontage Holdings's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
HKSE:01521 vs VRTX, REGN, RVMD: Days Payable Comparison
For the Biotechnology subindustry, Frontage Holdings's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Frontage Holdings Days Payable vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Frontage Holdings's Days Payable distribution charts can be found below:
* The bar in red indicates where Frontage Holdings's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Frontage Holdings's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Frontage Holdings (HKSE:01521) has a Days Payable of 20.43 as of Dec. 2025. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Frontage Holdings and its competitors. This is 14% below median its historical median of 23.81. Over the past decade, Frontage Holdings' Days Payable has ranged from 15.94 to 29.18. According to the industry distribution chart, Frontage Holdings ranks #629 out of 704 companies in the Biotechnology industry, placing it in the top 89.3%.
Is Frontage Holdings' Days Payable too high?
Frontage Holdings' current Days Payable of 20.43 is 14% below median its 10-year median of 23.81. Over the past 10 years, this metric has ranged from a low of 15.94 to a high of 29.18. The Biotechnology industry median Days Payable is 112.72. Frontage Holdings' value of 20.43 is 81.9% below this industry median. Based on the distribution chart, Frontage Holdings ranks #629 out of 704 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Frontage Holdings has a GF Score™ of 89/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Frontage Holdings' Days Payable compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Frontage Holdings ranks #629 out of 704 companies for Days Payable. This places Frontage Holdings in the lower half of its industry. The industry median Days Payable is 112.72. Frontage Holdings' value of 20.43 is 81.9% below this benchmark. Historically, Frontage Holdings' own Days Payable has ranged from 15.94 to 29.18 over the past decade. While the company's 10-year median is 23.81 vs. the industry median of 112.72, Frontage Holdings has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Biotechnology company?
The median Days Payable among Biotechnology companies is 112.72, based on 704 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Frontage Holdings's current Days Payable of 20.43 is 81.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Frontage Holdings and its competitors. For the Biotechnology industry, the median Days Payable is 112.72 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Frontage Holdings's current Days Payable is 20.43, which is 14% below median its own 10-year median of 23.81. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Frontage Holdings stock overvalued right now?
Based on GuruFocus' analysis, Frontage Holdings (HKSE:01521) is currently considered Modestly Undervalued. The stock's GF Value™ is HK$1.55, compared to a current price of HK$1.26 — trading 18.7% below its estimated fair value. The current Days Payable is 20.43, which is 14% below median its 10-year median of 23.81 and 81.9% below the Biotechnology industry median of 112.72. Frontage Holdings' overall GF Score™ is 89/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Frontage Holdings (HKSE:01521), the current Days Payable is 20.43 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Frontage Holdings (HKSE:01521) Overvalued in 2026?
Based on GuruFocus' analysis, Frontage Holdings stock appears to be undervalued.
The current stock price of HK$1.26 is trading 18.7% below its estimated GF Value™ of HK$1.55.
GuruFocus considers Frontage Holdings to be Modestly Undervalued.
Key valuation signals for HKSE:01521:
Days Payable: 20.43 (14% below median its 10-year median of 23.81)
GF Value™: HK$1.55 vs. price of HK$1.26 (18.7% below fair value)
Industry Position: 81.9% below the Biotechnology median (#629 of 704)
No single metric tells the full story. See the HKSE:01521 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Frontage Holdings Corp provides laboratory and related services to pharmaceutical and agrochemical companies. Its segments include North America and Europe segment, including drug discovery, drug development, pharmaceutical product development and laboratory testing in the USA, Canada and Europe; and PRC segment, including drug discovery, drug development, pharmaceutical product development and laboratory testing in the PRC. It derives majority of the revenue from North America and Europe segment. Geographically majority of the revenue is derived from USA and Canada.
89GF Score
Get the complete analysis for HKSE:01521
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:01521 has been successfully added to your 
